SCHEMBL20955151

SCHEMBL20955151

CC(C)(C)OC(=O)N1CCC2(CC1)OC(=O)c1cc(N)ccc12

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.49
USP30 Q70CQ3 1/20 0.41
HDAC2 Q92769 2/20 0.40
HDAC1 Q13547 1/20 0.40
SMARCA2 P51531 1/20 0.40
SMARCA4 P51532 1/20 0.40
PBRM1 Q86U86 1/20 0.40
GPR119 Q8TDV5 3/20 0.39
PDK2 Q15119 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
NPY5R Q15761 2/20 0.38
SCD5 Q86SK9 1/20 0.38
AVPR1A P37288 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
ATM Q13315 1/20 0.38
CCR5 P51681 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30508369 0.87 AVPR1A (0.48) USP30GPR119PDK2HRH3NPY5R
SCHEMBL12175490 0.85 HRH3 (0.52) HRH3NPY5R
SCHEMBL20602904 0.83 NR1H2 (0.50) NR1H2USP30SMARCA2SMARCA4PBRM1
SCHEMBL30109297 0.83 NR1H2 (0.50) NR1H2USP30SMARCA2SMARCA4PBRM1
SCHEMBL20955392 0.82 NPC1 (0.42) GPR119NPY5R
SCHEMBL17586448 0.80 ALK (0.43) USP30GPR119PDK2HRH3NPY5R
SCHEMBL350344 0.80 AVPR1A (0.48) USP30HRH3NPY5RSCD5AVPR1A
SCHEMBL30743086 0.79 NR1H2 (0.56) NR1H2USP30HDAC2HDAC1GPR119
SCHEMBL349129 0.78 HSD11B1 (0.55) USP30HRH3NPY5R
SCHEMBL20788641 0.77 NR1H2 (0.48) NR1H2USP30HDAC2HDAC1GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11414429-B2 Compound or pharmaceutically acceptable salt thereof RIKEN (JP) 2022-08-16 US disclosed
EP-3480198-B1 NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF RIKEN (JP) 2021-05-05 EP disclosed
US-20200172554-A1 NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF RIKEN (JP) 2020-06-04 US disclosed
EP-3480198-A1 NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF RIKEN (JP) 2019-05-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11414429-B2 Compound or pharmaceutically acceptable salt thereof DPP8, DPP7, AZI2 NR1H2 4096/4885USP30 2144/4885HDAC2 88/4885
US-20200172554-A1 NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DPP8, DPP7, AZI2 NR1H2 4051/4885USP30 1843/4885HDAC2 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.